534 related articles for article (PubMed ID: 15128818)
1. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
[TBL] [Abstract][Full Text] [Related]
3. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.
Barratt-Boyes SM; Soloff AC; Gao W; Nwanegbo E; Liu X; Rajakumar PA; Brown KN; Robbins PD; Murphey-Corb M; Day RD; Gambotto A
J Gen Virol; 2006 Jan; 87(Pt 1):139-149. PubMed ID: 16361426
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
Nanda A; Lynch DM; Goudsmit J; Lemckert AA; Ewald BA; Sumida SM; Truitt DM; Abbink P; Kishko MG; Gorgone DA; Lifton MA; Shen L; Carville A; Mansfield KG; Havenga MJ; Barouch DH
J Virol; 2005 Nov; 79(22):14161-8. PubMed ID: 16254351
[TBL] [Abstract][Full Text] [Related]
5. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.
Tan WG; Jin HT; West EE; Penaloza-MacMaster P; Wieland A; Zilliox MJ; McElrath MJ; Barouch DH; Ahmed R
J Virol; 2013 Feb; 87(3):1359-72. PubMed ID: 23175355
[TBL] [Abstract][Full Text] [Related]
7. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.
Abbink P; Lemckert AA; Ewald BA; Lynch DM; Denholtz M; Smits S; Holterman L; Damen I; Vogels R; Thorner AR; O'Brien KL; Carville A; Mansfield KG; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2007 May; 81(9):4654-63. PubMed ID: 17329340
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
[TBL] [Abstract][Full Text] [Related]
9. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
10. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
Sumida SM; Truitt DM; Kishko MG; Arthur JC; Jackson SS; Gorgone DA; Lifton MA; Koudstaal W; Pau MG; Kostense S; Havenga MJ; Goudsmit J; Letvin NL; Barouch DH
J Virol; 2004 Mar; 78(6):2666-73. PubMed ID: 14990686
[TBL] [Abstract][Full Text] [Related]
12. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.
Quinn KM; Da Costa A; Yamamoto A; Berry D; Lindsay RW; Darrah PA; Wang L; Cheng C; Kong WP; Gall JG; Nicosia A; Folgori A; Colloca S; Cortese R; Gostick E; Price DA; Gomez CE; Esteban M; Wyatt LS; Moss B; Morgan C; Roederer M; Bailer RT; Nabel GJ; Koup RA; Seder RA
J Immunol; 2013 Mar; 190(6):2720-35. PubMed ID: 23390298
[TBL] [Abstract][Full Text] [Related]
15. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys.
Sun Y; Bailer RT; Rao SS; Mascola JR; Nabel GJ; Koup RA; Letvin NL
J Virol; 2009 Oct; 83(20):10596-604. PubMed ID: 19656883
[TBL] [Abstract][Full Text] [Related]
16. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.
Cheng C; Gall JG; Nason M; King CR; Koup RA; Roederer M; McElrath MJ; Morgan CA; Churchyard G; Baden LR; Duerr AC; Keefer MC; Graham BS; Nabel GJ
J Virol; 2010 Jan; 84(1):630-8. PubMed ID: 19846512
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.
Cheng C; Gall JG; Kong WP; Sheets RL; Gomez PL; King CR; Nabel GJ
PLoS Pathog; 2007 Feb; 3(2):e25. PubMed ID: 17319743
[TBL] [Abstract][Full Text] [Related]
20. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
